Sinsin Pharmaceutical신신제약
002800 · KOSDAQ · ₩002800 · 신신제약
₩4,035▼ ₩25 (0.62%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩114B | ₩106B | ₩103B | ₩92B | ₩74B |
| Cost of sales | ₩71B | ₩70B | ₩69B | ₩62B | ₩52B |
| Gross profit | ₩43B | ₩36B | ₩33B | ₩30B | ₩22B |
| Operating income | ₩11B | ₩6.9B | ₩6B | ₩5.4B | −₩1.3B |
| Net income | ₩9.3B | ₩4.8B | ₩4.6B | ₩4.4B | −₩1.4B |
| Net income to shareholders | ₩9.3B | ₩4.9B | ₩4.7B | ₩4.4B | −₩1.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩137B | ₩129B | ₩124B | ₩121B | ₩114B |
| Current assets | ₩59B | ₩51B | ₩47B | ₩45B | ₩36B |
| Cash and equivalents | ₩3.9B | ₩540M | ₩346M | ₩2.2B | ₩799M |
| Total liabilities | ₩63B | ₩64B | ₩62B | ₩62B | ₩60B |
| Current liabilities | ₩60B | ₩59B | ₩52B | ₩42B | ₩34B |
| Borrowings | ₩44B | ₩45B | ₩44B | ₩43B | ₩46B |
| Total equity | ₩75B | ₩66B | ₩62B | ₩60B | ₩55B |
| Shareholders' equity | ₩75B | ₩66B | ₩62B | ₩60B | ₩55B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩8.6B | ₩5.9B | ₩3.9B | ₩5.5B | ₩23M |
| Capital spending | ₩1.6B | ₩1.5B | ₩5B | ₩907M | ₩2.7B |
| Free cash flow | ₩7B | ₩4.4B | −₩1.1B | ₩4.6B | −₩2.7B |
| Dividends paid | ₩910M | ₩910M | ₩759M | — | — |
Consolidated where available. Amounts in won.
Also known as: Sinsin Pharmaceutical / 신신제약 / 002800 / KRX:002800
Source: KRX statistical information